Changes in Soluble Tumour Necrosis Factor Receptor type 1 levels and early renal function decline in patients with diabetes.

2019-04-15

MacIsaac, Richard J

Farag, Matthew

Obeyesekere, Varuni

Clarke, Michele V

Boston, Ray

Ward, Glenn M

Jerums, George

Ekinci, Elif I

Diabetic kidney disease

GFR

nephropathy

sTNFR1

Journal Article

0000-0001-8058-6977

0000-0003-2372-395X

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

#PLACEHOLDER_PARENT_METADATA_VALUE#

10.1111/jdi.13061

The relationship between serial changes in soluble tumour necrosis factor receptor type 1 (TNFR1) levels and an early decline in estimated glomerular filtration rate (eGFR) decline remains to be defined. We found that in patients with an early decline in renal function (n=30), soluble TNFR1 values increased (2595±683 vs 3596±1203 pg/mL, p<0.001) as eGFR decreased (89±1 vs 51±2 mL/min/1.73m2 , p<0.001) over an eight year period. In contrast, there were no significant changes in soluble TNFR1 levels in patients with stable renal function (n=17). In a multi-level mixed effects regression model, changes in soluble TNFR1 levels were found to be independently associated with eGFR decline (Z=-4.31, p<0.001). An early decline in eGFR is associated with an increase in soluble TNFR levels; however the factors driving this increase and the possible pathological role that sTNFR1 plays in progressive DKD remains to be determined. This article is protected by copyright. All rights reserved.

link

Journal of Diabetes Investigation 2019; 10(6): 1537-1542

Journal of Diabetes Investigation